MAPT and Alzheimer disease: MD3.1 most efficiently immunoprecipitated tau seeds from control brain, while antibodies against R1 and more N-terminal residues more efficiently immunoprecipitated AD seeds versus antibodies directed against R3/R4 and more C-terminal residues (Fig. 9C).